Anvatabart opadotin

{
  "id": "MLC-T-ONC-011189",
  "term": "Anvatabart opadotin",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMAF) analog and potent microtubule inhibitor opadotin, with potential antineoplastic activity. Upon administration of anvatabart opadotin, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, opadotin binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of anvatabart opadotin, increases payload stability and optimizes its efficacy.",
  "synonyms": [
    "anti-HER2 ADC ARX788",
    "ADC ARX788",
    "anti-HER2 antibody-drug conjugate ARX788",
    "anti-Her2 Mab PAF- MMAF toxin oxime conjugate ARX-788"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anvatabart-opadotin/"
}